|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Ra Pharmaceuticals Inc (RARX)
Trading: BUY @ $46.9
Signal Strength: STRONG
Indicator is best used in conjunction with additional indicators as it has the ability to highlight potential overbought or oversold levels. This indicator utilizes upper and lower bands to visually represent price extremes associated with the bands. Additional value can be added to the trading strategy by accessing divergences between price and volume.
Ra Pharmaceuticals Inc (NASDAQ:RARX) is currently Oversold highlighting the potential for a short term trend reversal in the upward direction.
Acceleration bands serve as a trading envelope using an instrument’s typical volatility over a standard setting of 20 bars. The user may change the input (close) period length and multiplier factor.
Calculation: Acceleration Bands:
1) Upper band = ( High * ( 1 + 2 * (((( High – Low )/(( High + Low ) / 2 )) * 1000 ) * Factor )));
2) Lower band = ( Low * ( 1 – 2 * (((( High – Low )/(( High + Low ) / 2 )) * 1000 ) * Factor )));
3) Where Factor=0.001
PROFILE: Ra Pharmaceuticals Inc (RARX)
Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
|SYRS Syros Pharmaceuticals||8.2||4.9||153,243||-6.07||BEARISH|
|FARM Farmer Brothers||13.38||4.4||116,584||-1.89||BEARISH|
|TRUP Trupanion Inc||33.32||4.2||261,897||-6.24||BEARISH|
|BCOR Blucora Inc||23.41||3.2||401,986||-7.71||BEARISH|
|OTIC Otonomy Inc||3.65||3.1||161,652||-2.67||BEARISH|
|VSEC VSE Corporation||34.74||3||14,243||-4.91||BEARISH|
|VRAY Viewray Inc||3.06||3||3,697,594||-11.21||BEARISH|
|ACIU AC Immune||9.65||2.7||62,564||-0.92||BEARISH|